Yahoo
Shenzhen - Delayed Quote CNY

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ)

15.48 +0.24 (+1.57%)
At close: October 30 at 3:04:00 PM GMT+8
Chart Range Bar
Loading chart for 002603.SZ
  • Previous Close 15.24
  • Open 15.18
  • Bid 15.48 x --
  • Ask 15.49 x --
  • Day's Range 15.13 - 15.60
  • 52 Week Range 14.22 - 21.58
  • Volume 15,300,598
  • Avg. Volume 17,906,120
  • Market Cap (intraday) 25.863B
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) 18.65
  • EPS (TTM) 0.83
  • Earnings Date --
  • Forward Dividend & Yield 0.80 (5.17%)
  • 1y Target Est 20.51
  • Moby Rating Neutral

Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine in China and internationally. It offers dietary supplements, and healthy food and drinks; patent TCM products for respiratory health, cardiovascular disease, diabetes, mellitus, oncology, urologic disease, sleep-improving, and anti-aging; disinfection and personal protective equipment products; and TCM formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.

www.yiling.cn

11,343

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002603.SZ
6.38%
SSE Composite Index (000001.SS)
9.32%

1-Year Return

002603.SZ
8.73%
SSE Composite Index (000001.SS)
9.73%

3-Year Return

002603.SZ
25.59%
SSE Composite Index (000001.SS)
19.11%

5-Year Return

002603.SZ
6.60%
SSE Composite Index (000001.SS)
1.46%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY19
Revenue 1.36B
Earnings 120.15M
Profit Margin 8.82%

Q4

FY18

Q1

FY19

Q2

FY19

Q3

FY19

0
500M
1B
2B
5.0%
10.0%
15.0%

Analyst Insights

View More

Analyst Price Targets

19.62
20.51 Average
15.48 Current
21.40 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.42%

  • Return on Assets (ttm)

    7.40%

  • Return on Equity (ttm)

    12.59%

  • Revenue (ttm)

    7.93B

  • Net Income Avi to Common (ttm)

    1.38B

  • Diluted EPS (ttm)

    0.83

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.52B

  • Total Debt/Equity (mrq)

    0.19%

  • Levered Free Cash Flow (ttm)

    957.34M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: